These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19799829)

  • 1. Safety of conventional systemic agents and biologic agents in the treatment of psoriasis.
    Bissonnette R; Ho V; Langley RG
    J Cutan Med Surg; 2009; 13 Suppl 2():S67-76. PubMed ID: 19799829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.
    Ahn CS; Dothard EH; Garner ML; Feldman SR; Huang WW
    J Am Acad Dermatol; 2015 Sep; 73(3):420-8.e1. PubMed ID: 26184440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic therapy in psoriasis: perspectives on associated risks and patient management.
    Papp KA; Dekoven J; Parsons L; Pirzada S; Robern M; Robertson L; Tan JK
    J Cutan Med Surg; 2012; 16(3):153-68. PubMed ID: 22713438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical monograph for drug formulary review: systemic agents for psoriasis/psoriatic arthritis.
    Fisher VS
    J Manag Care Pharm; 2005; 11(1):33-55. PubMed ID: 15667232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic therapies in psoriasis: a new therapeutic approach.
    Gisondi P; Girolomoni G
    Autoimmun Rev; 2007 Sep; 6(8):515-9. PubMed ID: 17854741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriatic nail disease: quality of life and treatment.
    Gupta AK; Cooper EA
    J Cutan Med Surg; 2009; 13 Suppl 2():S102-6. PubMed ID: 19799826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatments for psoriasis and the risk of malignancy.
    Patel RV; Clark LN; Lebwohl M; Weinberg JM
    J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological treatments for moderate-to-severe psoriasis: indirect comparison.
    Galván-Banqueri M; Marín Gil R; Santos Ramos B; Bautista Paloma FJ
    J Clin Pharm Ther; 2013 Apr; 38(2):121-30. PubMed ID: 23442134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
    Schmitt J; Rosumeck S; Thomaschewski G; Sporbeck B; Haufe E; Nast A
    Br J Dermatol; 2014 Feb; 170(2):274-303. PubMed ID: 24131260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate.
    Farhangian ME; Feldman SR
    Am J Clin Dermatol; 2015 Aug; 16(4):285-294. PubMed ID: 25963062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.
    Sorenson E; Koo J
    J Dermatolog Treat; 2015; 26(6):493-501. PubMed ID: 25886082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
    JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe and acute complications of biologics in psoriasis.
    Oussedik E; Patel NU; Cash DR; Gupta AS; Feldman SR
    G Ital Dermatol Venereol; 2017 Dec; 152(6):586-596. PubMed ID: 28895664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient Adherence to Biologic Agents in Psoriasis.
    Hsu DY; Gniadecki R
    Dermatology; 2016; 232(3):326-33. PubMed ID: 27093295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interpretation of long-term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials.
    Langley RG; Reich K
    Br J Dermatol; 2013 Dec; 169(6):1198-206. PubMed ID: 23937204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biologic therapies in the treatment of psoriasis].
    Farhi D; Dupin N
    Presse Med; 2009 May; 38(5):832-43. PubMed ID: 19282134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
    J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From conventional to cutting edge: the new era of biologics in treatment of psoriasis.
    Tzu J; Kerdel F
    Dermatol Ther; 2008; 21(2):131-41. PubMed ID: 18394087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.